In
the United States alone, an estimated 26 million people have Type 2 diabetes
while another 80 million or so people are pre-diabetic. Recognizing that there
are urgent, unfulfilled medical needs for both the pre-diabetic and diabetic
community, Boston Therapeutics is concentrating on creating better technology
to prevent diabetes and its complications.
Considering
the varied and dangerous complications that stem from uncontrolled diabetes
(such as heart disease, stroke, and kidney damage), Boston Therapeutics’ goal
is to better control glucose levels in patients throughout the day using
innovations in complex carbohydrate chemistry.
The
key diabetic solution in the company’s arsenal is PAZ320, a non-systemic,
non-toxic chewable drug candidate that is intended to be taken before meals to
reduce the post-meal elevation of blood glucose in patients living with Type 2
diabetes. PAZ320 slows down the enzymes that release glucose from complex
carbohydrates in foods during digestion and thereby reduces the amount of
glucose absorbed through the intestine.
Boston
Therapeutics is developing the PAZ320 drug for potential use with metformin, a
popular anti-diabetic drug, and as a better alternative to Acarbose, which has
side effects and limited functionality. PAZ320 has already completed a Phase 2
clinical trial to reduce post-meal glucose elevation and the company hopes to
take it to Phase 3 trial by the third quarter of 2014.
Alongside
PAZ320, Boston Therapeutics has two other products in the pipeline: IPOXYN and
OXYFEX.
IPOXYN,
a universal oxygen carrier and cell bodyguard, is an injectable drug candidate
for the prevention of necrosis, the death of cells in an organ or tissue due to
a failure of blood supply. IPOXYN would also be appropriate for the treatment of
hypoxia, a deficiency in the amount of oxygen reaching the tissues, as well as
other ischemic conditions which may lead to necrosis. IPOXYN oxygen carriers
are in the pre-clinical stage of drug development.
OXYFEX,
a reproduction of IPOXYN, is Boston Therapeutics’ offering to the veterinary
market. OXYFEX is able to serve as an oxygen delivery mechanism for animals
suffering from damaged or ischemic tissue due to traumatic and surgical blood
loss.
Boston
Therapeutics has engaged in designing, producing, and marketing novel compounds
and therapeutic drugs that address diabetes and other inflammatory diseases
since its start in 2009.
For
more information, visit www.bostonti.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
